Perfluorohexyloctane eye drops is the only drug in China approved for treating Dry Eye Disease (DED) related to Meibomian Gland Dysfunction (MGD), its efficacy and safety in the clinical practice of treating DED related to MGD in the real world, whether in combination with or without various other treatment methods (other drugs or physical therapy) , remain to be explored. This study aims to collect data on the treatment of DED related to MGD with perfluorohexyloctane under real medical conditions. Through analysis, it seeks to obtain clinical evidence of the product's application value and potential benefits or risks, providing evidence for the treatment of DED elated to MGD with perfluorohexyloctane under real medical conditions.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Timeframe: Week 12
Incidence of adverse events assessed by the investigator as related to the study drug
Timeframe: Week 12
Uncorrected Visual Acuity [UCVA]
Timeframe: Week 12
Intraocular Pressure [IOP]
Timeframe: Week 12
Fundus Examination Findings
Timeframe: Week 12
Change in SPEED (Standard Patient Evaluation of Eye Dryness) Questionnaire Score at week 12
Timeframe: Baseline and Week 12